Embryonic stem cells, which are characterized by pluripotency and self-renewal, have recently been highlighted in drug discovery. In particular, the potential of ES cells to differentiate into specific-cell types make them an extremely useful tool in the evaluation of the biological activity of test compounds. Honokiol, a major neolignan derived from the bark of Magnolia obovata, has been shown an anti-tumor activity. However, the precise mechanism of action in the anti-tumor activity of honokiol is still poorly understood. Here, we evaluated the antiangiogenic activity of honokiol using mouse ES cell-derived embryoid bodies. mES-derived EBs were formed using hanging drop cultures and vascular formation was induced on gelatincoated plates in EGM-2 medium. The growth inhibition of honokiol was found to be more sensitive in the differentiated EB-derived endothelial cells compared to the undifferentiated EB-derived cells. Honokiol also inhibited the vascular formation of mES cells on 3-D collagen gel and decreased the expression of endothelial biomarkers VEGFR2 and PECAM in the differentiated EB-derived endothelial cells. In addition, honokiol suppressed the MAPK and mTOR signaling pathways in the EB-derived endothelial cells. Therefore, the anti-angiogenic activity of honokiol is associated in part with the suppression of PECAM and MAPK/mTOR pathways in EB-derived endothelial cells.
Introduction
Embryonic stem (ES) cells were �irst established from the inner cell mass of mouse blastocysts [1] . Mouse embryonic stem (mES) cells can be expanded continuously in culture with mitotic inactivated embryonic �ibroblast cells, maintaining multi-lineage differentiation capability [1] . The differentiation of embryonic stem cells from embryo-like aggregates, embryoid bodies (EBs), could potentially result in the development of many cell types such as hematopoietic, neuronal, cardiomyocytes, muscle cells, epithelial and endothelial cell lineages [2] . ES cells have been shown to be a useful tool for the study of vasculogenesis and angiogenesis including angioblast differentiation, proliferation, migration, endothelial cellcell adhesion and vascular morphogenesis [3] [4] [5] . A diverse approach has evolved to induce differentiation of ES cells into endothelial cells. One promising approach was conducted using EBs for further differentiation from ES cells. EBs represents a good in vitro model not only for vasculogenesis (the formation of vessels from endothelial progenitors) but also for angiogenesis (the formation of new vessels from preexisting ones) in a 2-D or 3-D culture system [6, 7] . Therefore, the ES/EB system allows for the study of both vasculogenesis and angiogenesis. This unique property confers superiority over all other in vitro angiogenesis models. In particular, EB-derived endothelial cells have been considered a useful tool to study endothelial cell biology and developmental processes. This process is characterized by the expression of endothelial cell-speci�ic molecules during the formation of vascular structures in ES-derived EBs. The expression of a number of biomarkers, including VEGFR2 and PECAM, has been reported in vasculogenesis [8, 9] .
Angiogenesis is the formation of new blood vessels from the pre-existing blood vasculature by the sprouting, splitting and remodeling of the vascular network. Angiogenesis is a complex process that results from an ordered set of events involving endothelial cell activation, growth, migration and capillary morphogenesis. VEGF is one of the most essential factors regulating angiogenesis. VEGF activity is mediated by the VEGF receptors (VEGFR)-1 (Flt-1, 180 kDa) and VEGFR-2 (KDR/Flk-1, 200 kDa), both of which are almost exclusively expressed in endothelial cells [10] . The binding of VEGF to VEGFRs and the subsequent ligand-induced dimerization of these receptors stimulate their intrinsic tyrosine kinase activity, which triggers key angiogenic responses in endothelial cells, including proliferation, migration, differentiation and protection from apoptosis. These effects are mediated via a number of different signaling cascades [11] . VEGF induces autophosphorylation of VEGFR2, followed by activation of downstream signaling pathways such as MAPK and mTOR stimulating angiogenesis. VEGF is also known to activate three MAPKs including ERK [12] , SAPK/JNK [13] , Akt [14] , p38 MAPK [15] and mTOR [16, 17] in endothelial cells. mTOR is a serine/threonine protein kinase that exists as two functional protein complexes, mTORC1 and mTORC2 [18] . This kinase also regulates cell growth, cell cycle progression and angiogenesis by phosphorylating of eukaryotic initiation factor 4E binding protein 1. Indeed, the activation of the MAPK/mTOR signaling pathway in endothelial cells promotes their survival when cultured in vitro [19] and in the tumor vasculature in vivo [20] . PECAM, a member of the immunoglobulin super-family, is expressed by endothelial cells and a subset of hematopoietic cells in the adult organism [21] . Additionally, undifferentiated ES cells have also been shown to express PECAM [22] . Thus, PECAM is a cell surface marker for endothelial cells and endothelial sprouting in vasculogenesis and angiogenesis [23] .
Anti-angiogenic strategies have been proven to be a useful approach in patients with a high risk of developing cancer, cancer recurrence or the development of metastases. The identi�ication of low-toxic anti-angiogenic or angio-preventive compounds derived from natural products is considered an achievable goal in the search for anti-cancer or cancer chemopreventive agents. In a previous study, we reported that mES might be an alternative model in which to evaluate the effect of 5-FU on vasculogenesis [24, 25] . In our continuous effort to identify anti-cancer agents, we established a mES in vitro screening system to evaluate the anti-angiogenic effects of natural product-derived compounds. Honokiol is a neolignan from the bark of Magnolia obovata Thunberg (Magnoliaceae) that has traditionally been used to enhance the function of the gastrointestinal tract in Asian countries. Honokiol was also found to be a potent scavenger of hydroxyl radicals [26, 27] . Recent studies have also reported various biological effects of neolignans including neuroprotection against oxidative stress [28] [29] [30] , suppression of metastasis [14] , anti-in�lammatory activity [31, 32] , anti-angiogenesis [33, 34] and anti-proliferation in a wide range of cancer cell types [35] [36] [37] . Honokiol is an especially potent inhibitor of angiogenesis that attenuates endothelial cell proliferation and the growth of angiosarcomas [14] . However, the precise mechanism of action of the anti-angiogenic activity of honokiol is still poorly understood.
In the present study, we demonstrated that the anti-angiogenic activity of honokiol is associated with the suppression of PECAM expression and the down-regulation of MAPK/ mTOR pathways in mES-derived endothelial cells.
Materials and Methods

Test compounds
Honokiol (purity > 98%, Fig. 2 ) isolated from the bark of Magnolia obovata was provided by Dr. K Bae [27] . The compound was dissolved in 100% DMSO.
Cell culture
Mouse D 3 ES cells (ATCC Cat. No. CRL-1934, Rockville, MD, USA) were co-cultured with mitomycin C treated mouse embryonic �ibroblasts in high glucose DMEM (Invitrogen, Carlsbad, CA, USA) containing 15% fetal bovine serum (Hyclone, Ogden, UT, USA), 1000 U/ ml of LIF (Chemicon, Temecula, CA, USA), and basic ES medium components [50 U/ml of penicillin and 50 µg/ml streptomycin (Invitrogen, Carlsbad, CA, USA), 1% non-essential amino acids (Invitrogen, Carlsbad, CA, USA) and 0.1 mM β-mercaptoethanol (Invitrogen, Carlsbad, CA, USA)]. The hanging drop method (20 µl per drop; 1 x 10 5 cells/ml) was used to induce differentiation as described by Heuer and colleagues [38] . The EBs were formed by incubating hanging drop cultures for three days. The resulting EBs was transferred onto gelatin-coated chamber slides (Nunc, Denmark) or 60 mm dishes to allow for attachment. Endothelial cell differentiation was induced in EBs by switching culture conditions to medium containing EBM-2, 5% FBS, growth factor cocktail, and ascorbic acid (EGM2-MV Bullet Kit; Lonza, Walkersville, MD, USA). Viable cells were directly observed under an inverted phase contrast light microscope (Olympus Optical Co. Ltd., Tokyo, Japan).
ES cell characterization assay
Alkaline phosphatase activity and SSEA-1 of cultured cells were analyzed according to manufacturer's instruction (Kit, Chemicon, Temecula, CA, USA).
Growth inhibition assay
The growth inhibition activity in cultured mES cells was determined by MTT assays with or without LIF as previously described [39] . Brie�ly, cells (0.3-1 x 10 4 cells/ml) were seeded into a 96-well plate and grown in the presence of test compounds. At the early stage (differentiation day 1) or the late stage (differentiation day 10), the cells were exposed to various concentrations of compounds for 24 hrs. After incubation, MTT solution was added and incubated for an additional 4 hrs. The resulting formazan was dissolved with DMSO and the absorbance was detected at 570 nm with a VersaMax ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA). After treatment of honokiol for 24 hrs at differentiation day 10, the effects of honokiol on cytotoxicity were tested using the CytoTox 96 ® Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA). The viability and cytotoxicity activity of honokiol were calculated as a percentage, relative to solvent-treated control. The IC 50 values were calculated using a non-linear regression analysis of percent growth versus concentration.
Kim/Bae/Park/Bae/Lee: Honokiol Inhibits Angiogenesis via PECAM Suppression in mES Cells Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry from 2 µg of total RNA using an oligo (dT) primer and a SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. First-strand cDNAs were ampli�ied in a �inal volume of 25 µl containing 0.5 U Taq DNA polymerase (TaKaRa Bio Inc., Otsu, Shiga, Japan) and 10 pmol of each target primer. PCR conditions were as follows: 5 min at 94°C, 30 ampli�ication cycles (denaturation at 94°C for 30 sec, annealing at 55-60°C for 30 sec, and extension at 72°C for 30 sec), followed by a �inal extension at 72°C for 5 min. The ampli�ied products were separated on 1.5% agarose gels. The gel was stained with SYBR ® Gold staining solutions (Invitrogen, Carlsbad, CA, USA) and visualized under the UV transilluminator (GelDoc™ XR, BioRad Molecular Imager, USA). cDNA samples were adjusted to yield equal GAPDH ampli�ications. Sequences of the PCR primers are listed in Table 1 .
Western blot analysis
Cells were treated with honokiol for 24 hrs. Harvested cells were lysed in protein extraction solution (Intron Biotechnology, Inc., Kyunggi, Korea) containing protease inhibitors and phosphatase inhibitors for 10 min at 4°C. Protein concentration was measured by the Bradford assay. Equal amounts (40 µg) of protein samples were subjected to 6-15% SDS-PAGE. Separated proteins were transferred to PVDF membranes (Millipore, Bedford, MA, USA). Membranes were incubated with primary antibodies diluted (1:200-1:1000) in 5% non-fat dry milk in TBST overnight at 4°C. Membranes were washed three times with TBST and incubated with corresponding secondary antibodies. Protein bands were detected with an enhanced chemiluminescence detection kit (Intron Biotechnology, Inc., Kyunggi, Korea) and a LAS-1000 Imager (Fuji Film Corp., Tokyo, Japan). Anti-PECAM, anti-ERK, anti-phospho-ERK, anti-p38α, anti-phospho-p38, and secondary antibodies were from Santa Cruz Biotechnology (Santa Cruze Biotechnology, Santa Cruz, CA, USA). Anti-Akt, anti-phospho-Akt, anti-SAPK/JNK, anti-phospho-SAPK/JNK, anti-mTOR, anti-phosphomTOR anti-4EBP1, anti-phospho-4EBP1, PD98059, and LY294002 were purchased from Cell Signaling Biotechnology (Cell Signaling Biotechnology, Danvers, MA, USA). β-actin antibody was from Sigma (Sigma, St. Louis, MO, USA).
Immunocytochemistry
Cells were plated onto cover slips and induced endothelial-like cells with EGM-2 medium for 10 days. The endothelial like-cells incubated with honokiol for 24 hrs. After incubation, the cells were �ixed with 4% paraformaldehyde and incubated overnight at 4°C. The cells were blocked with blocking solution containing 1% BSA/PBS for 30 min, and then incubated with rat anti-mouse PECAM (1:200) (Santa Cruze Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. After washing, the cells were incubated with Alexa Fluor 594-labeled chicken anti-rat IgG (1:1000) (Invitrogen, Carlsbad, CA, USA). After staining, the cover slips were mounted with medium containing DAPI (Vector Laboratories, Burlingame, CA, USA). Confocal microscopy was performed on a Zeiss Model 710 (Carl Zeiss, Jena, Germany).
Results
Induction of differentiation for endothelial-like cells from mES cells
We primarily employed EBs formed from mES cells to generate endothelial cells. EBs were formed by a hanging drop culture of mES cells and transferred to an adherent culture using gelatin-coated plates. The morphological changes of endothelial cells formed from mES-derived EBs were found to be dependent on the stage of differentiation (Fig. 1A) . Especially, the morphological changes of mES-derived endothelial cells show the spreading from the center part of mEB (Fig. 1A-c) and the enhancing for proliferation and differentiation through cell-to-cell contact (marked an arrow) by migration (Fig. 1A-d) . As shown in Fig.  1B , mES cells expressed high levels of alkaline phosphatase activity, and SSEA-1 recognizing speci�ic cell surface antigens. RT-PCR analysis showed that the expression of endothelial biomarkers including VEGFR2 and PECAM was increased in EB-derived endothelial cells cultured for 11 days. These events were also highly correlated with decreased expression of OCT4, an undifferentiated or stemness biomarker, during the endothelial differentiation of cells derived from mES cells (Fig. 1C) . Additionally, the expression of PECAM in EB-derived endothelial cells was also increased and capillary-like structures were observed on day 4 and day 11 by immunocytochemistry (Fig. 1D) . These results suggest that the established mES-derived EBs were capable of differentiating into endothelial cells. The induction of differentiation was also con�irmed by the expression of endothelial cell biomarkers at the mRNA and protein levels. The expression of PECAM was consistently increased depending on the endothelial differentiation stage.
Inhibition of the EB-derived differentiated endothelial cell growth by honokiol
To validate the usefulness of the mES-derived endothelial cells, the effects of honokiol on the growth of these cells were determined by the MTT assay. mES-derived endothelial cells at different stages of differentiation were treated with honokiol for 24 hrs. As shown in Fig. 3A , The growth inhibition in the early stage (differentiation day 1) and late stage (differentiation day 10) cells after 24 hrs of incubation with honokiol was signi�icantly different (p<0.05). The IC 50 values were 43 and 32 µM, respectively (Fig. 3A) . These data suggest that the differentiated endothelial cells derived from mES cells are more sensitive to honokiol-mediated inhibition of cell growth than undifferentiated mES-derived cells. To further determine the concentration ranges of honokiol without cytotoxicity in the differentiated endothelial-like cells, the cells were treated with honokiol (0 -100 µM) for 24 hrs and analyzed the cytotoxicity using LDH leakage assays (Fig. 3B) . Over 50 µM honokiol treatment showed a cytotoxic effect. Therefore, the further analysis of biological activities of honokiol was performed under 20 µM in the differentiated endothelial-like cells.
Suppression of honokiol on the expression of VEGFR2 and PECAM
To determine whether honokiol-mediated the inhibition of endothelial cell growth was associated with the suppression of endothelial biomarker expressions, the EB-derived After treatment, the gene and protein expression of the endothelial speci�ic biomarkers VEGFR2 and PECAM were analyzed. As shown in Fig. 4A , honokiol dose-dependently suppressed the expressions of mRNA of VEGFR2 and PECAM. The suppressive expression of VEGFR2 and PECAM protein was also found by honokiol treatment (Fig. 4B) , indicating that honokiol suppressed the expression of VEGFR2 and PECAM in the mRNA and protein level. The anti-angiogenic activity of honokiol was also assessed by measuring the expression of the endothelial biomarker PECAM in a 2-dimensional (2-D) culture. As shown in Fig.  4C -a, PECAM was easily detected by immuno�luorescence in the EB-derived endothelial cells. However, the expression of PECAM was attenuated with honokiol treatment in a concentration-dependent manner (Fig. 4C-b, 4C-c) .
Honokiol-mediated inhibition of sprouting angiogenesis in embryoid body derived from mES cells
Three-dimensional (3-D) collagen gel has previously been used to induce vascular tube formation. In this study, tube formation was induced by the incubation of mES-derived EBs in EGM-2 medium. The mES-derived EBs were cultured in suspension containing EGM-2 medium for 7 days, then plated in type-I collagen gel solution and �inally incubated in EGM-2 medium with test compounds for 4 days. As shown in Fig. 4D -a, the morphology of the vascular sprout in EB-derived endothelial cells was observed after 4 days of induction. When embryoid bodies were grown in the presence of honokiol (5, or 10 µM), vascular sprouting was completely blocked while control group greatly accelerated vascular tube sprouting and extensive network of cellular outgrowths (Fig. 4D-E) .
In addition, the inhibition of vascular sprouting by honokiol in the EB-derived endothelial cells was also con�irmed by the suppression of PECAM expression determined using the immuno�luorescence staining (Fig. 4F) . This result suggests that honokiol may inhibit vascular sprouting activity. These data suggest that honokiol have anti-angiogenic activity in EB-derived endothelial cells in 2-D and 3-D culture system. signalings. These data suggest that the suppression of VEGFR2 and PECAM by honokiol is in part mediated by the down-regulation of MAPK/mTOR signalings in the endothelial cell proliferation and angiogenesis.
Discussion
We established methods to differentiate mouse embryonic stem cells into endotheliallike cells and vessel formations. Further studies were performed to determine the utility of the model in evaluating the anti-angiogenic activity and its mechanism of action of honokiol in EB-derived endothelial cells. To our knowledge, this is the �irst report to evaluate the anti-angiogenic activity and its mechanism of action of honokiol using embryonic stem cells. Because anti-angiogenic compounds are potential cancer chemotherapeutic agents, we evaluated the anti-angiogenic activity of honokiol in established assay systems using the EBderived endothelial cells. Although neolignans including honokiol have been reported to have potent anti-proliferative and anti-angiogenic activity [14, 42, 43] , the precise mechanism of action of the anti-angiogenic effects of honokiol in in vitro and in vivo systems are not well understood. To establish mES-derived endothelial cells, we formed EBs with the hanging drop method using mES cells [38] . The EBs were differentiated in a gelatin-coated plate and the differentiation stage was monitored by measuring expression of the endothelial cell biomarkers VEGFR2 and PECAM.
In the present study with mES-derived EBs, we found that the expression of VEGFR2 was dependent on the stage of endothelial cell differentiation; thus, VEGFR2 expression might re�lect a commitment to differentiation to an endothelial lineage. PECAM was also expressed in undifferentiated mES cells and the expression level was increased by differentiation into endothelial cells. These results are consistent with previous studies that examined expression of PECAM in endothelial cells [44] . We next validated the usefulness of the EBderived endothelial cells in determining the anti-angiogenic potential of honokiol in several assay systems. Honokiol suppressed the expression of VEGFR2 and PECAM in the EB-derived endothelial cells. This result suggests that the anti-angiogenic activity of honokiol might be associated with the suppression of VEFGR2 and PECAM expression in endothelial cells. In angiogenesis, MAP kinases are activated by various stimuli including VEGF in endothelial cells and regulate multiple critical steps by phosphorylating different downstream substrates such as mTOR [45] . MAPK/mTOR signaling is one of the critical molecular events during growth, survival and migration in VEGF-induced angiogenesis of vascular endothelial cells [46, 47] . To determine whether the anti-angiogenic activity of honokiol is associated with the modulation of MAPK/mTOR signaling pathways the expression of MAPK/mTOR signaling molecules was determined in the EB-derived endothelial cells. Honokiol suppressed the phosphorylation of ERK1/2, SAPK/JNK, Akt, mTOR and 4EBP1 in the EB-derived endothelial cells. This might be one plausible mechanism of action for the anti-angiogenic or anti-proliferative activity of honokiol in endothelial cells. Because angiogenesis involves endothelial cell migration and proliferation within a collagen rich extracellular matrix, we established an in vitro angiogenic sprouting model system using mES-derived three-dimensional EB models [48] . When mESderived EBs matured in a type-I collagen gel they formed capillary-like structures as observed by morphological changes (3-D culture) and expression of PECAM (2-D culture). In this angiogenic sprouting model treatment with honokiol blocked the formation of the primitive vascular network structures in 17-day-old mES-derived EBs. This result also con�irmed that honokiol inhibited angiogenic sprouting of endothelial cells.
In summary, the present study shows that mES-derived EBs might provide useful models to study the early differentiation and development of blood vessels and angiogenesis, and also to use as a tool in the screening of pharmacologically interesting compounds. Additionally, the mES-derived EB model system was used to demonstrate that the anti-angiogenic activity mediated by honokiol involved the suppression of the endothelial biomarkers VEGFR2 and PECAM, and the modulation of MAPK/mTOR signaling pathways.
